Literature DB >> 33457117

Plasma Lipids as Biomarkers for Alzheimer's Disease: A Systematic Review.

Mehak Agarwal1, Safeera Khan1.   

Abstract

Alzheimer's disease (AD) is caused by several risk factors leading to dementia. It's diagnosis usually depends on clinical presentation and certain biomarkers in the cerebrospinal fluid (CSF). The brain has a high content of cholesterol and the metabolism of cholesterol in the brain can be associated with beta-amyloid plaques formation, which is seen in Alzheimer's disease. Given these implications, we studied if plasma lipid levels can vary in Alzheimer's disease and if these can be used as biomarkers to diagnose and predict the progression of Alzheimer's disease. Certain mutations in the brain cholesterol transport receptors and proteins and their association with Alzheimer's were also studied. This systematic review abides by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched multiple databases, such as Pubmed, Google Scholar, Pubmed central, ScienceDirect, Web of Science, and Medline with the help of keywords like Alzheimer's disease, cognitive impairment, plasma lipid biomarkers, cholesterol, brain cholesterol metabolism separately and in combination with each other. We collected 49 quality appraised articles on the association between plasma lipids and Alzheimer's disease and the genetic mutations in alleles related to cholesterol metabolism and Alzheimer's disease by applying the inclusion and exclusion criteria. Based on the finding of the studies reviewed, we found an association between plasma lipids, polymorphisms in genes associated with cholesterol transport, and Alzheimer's disease. Increased serum low-density lipoprotein (LDL-C), triglycerides (TG), total cholesterol (TC), sphingolipids, 24S hydroxycholesterol (24S-HC), 27O hydroxycholesterol (27O-HC) was associated with Alzheimer's. Decreased high-density lipoprotein (HDL-C) and phospholipids were noticed. Genetic mutations in apolipoprotein E (ApoE), apolipoprotein B (ApoB), apolipoprotein A (ApoA), ATP binding cassette transporter 1 (ABCA1), ATP binding cassette transporter 7 (ABCA7), amyloid precursor protein (APP), cytochrome P450 family 46 subfamilies A member 1 (CYP46A1), presenilin 1 (PSEN1), presenilin 2 (PSEN2) are also associated with increased risk of Alzheimer's disease. This study found an association between plasma lipids and Alzheimer's, proving that plasma lipids can be used as biomarkers for early diagnosis of Alzheimer's disease. It may also help predict the prognosis and stage the disease severity. Further studies are needed to find out the exact mechanism behind these changes.
Copyright © 2020, Agarwal et al.

Entities:  

Keywords:  alzheimers disease; brain cholesterol metabolism; cholesterol; cognitive impairment; plasma lipid biomarkers

Year:  2020        PMID: 33457117      PMCID: PMC7797449          DOI: 10.7759/cureus.12008

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  47 in total

Review 1.  Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis.

Authors:  Hua-Long Wang; Yan-Yong Wang; Xin-Gang Liu; Sheng-Han Kuo; Na Liu; Qiao-Yun Song; Ming-Wei Wang
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

2.  2009 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2009-05       Impact factor: 21.566

3.  Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis.

Authors:  Petroula Proitsi; Min Kim; Luke Whiley; Andrew Simmons; Martina Sattlecker; Latha Velayudhan; Michelle K Lupton; Hillka Soininen; Iwona Kloszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Simon Lovestone; John F Powell; Richard J B Dobson; Cristina Legido-Quigley
Journal:  Alzheimers Dement       Date:  2016-09-28       Impact factor: 21.566

Review 4.  Cholesterol in brain disease: sometimes determinant and frequently implicated.

Authors:  Mauricio G Martín; Frank Pfrieger; Carlos G Dotti
Journal:  EMBO Rep       Date:  2014-09-15       Impact factor: 8.807

5.  Cholesterol in mild cognitive impairment and Alzheimer's disease in a birth cohort over 14 years.

Authors:  P Toro; Ch Degen; M Pierer; D Gustafson; J Schröder; P Schönknecht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11-17       Impact factor: 5.270

6.  ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease.

Authors:  Hussein N Yassine; Qingru Feng; Jiarong Chiang; Larissa M Petrosspour; Alfred N Fonteh; Helena C Chui; Michael G Harrington
Journal:  J Am Heart Assoc       Date:  2016-02-12       Impact factor: 5.501

Review 7.  Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis.

Authors:  Kaarin J Anstey; Kimberly Ashby-Mitchell; Ruth Peters
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet Neurol       Date:  2018-11-26       Impact factor: 44.182

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

View more
  16 in total

1.  Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.

Authors:  Jens Pahnke; Pablo Bascuñana; Mirjam Brackhan; Katja Stefan; Vigneshwaran Namasivayam; Radosveta Koldamova; Jingyun Wu; Luisa Möhle; Sven Marcel Stefan
Journal:  Free Neuropathol       Date:  2021-12-13

Review 2.  Development of Alzheimer's Disease Biomarkers: From CSF- to Blood-Based Biomarkers.

Authors:  Sakulrat Mankhong; Sujin Kim; Seongju Lee; Hyo-Bum Kwak; Dong-Ho Park; Kyung-Lim Joa; Ju-Hee Kang
Journal:  Biomedicines       Date:  2022-04-05

3.  Targeted Metabolomic Analysis in Alzheimer's Disease Plasma and Brain Tissue in Non-Hispanic Whites.

Authors:  Karel Kalecký; Dwight C German; Albert A Montillo; Teodoro Bottiglieri
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

4.  Effects of Medicare comprehensive medication review on racial/ethnic disparities in nonadherence to statin medications among patients with Alzheimer's Disease: an observational analysis.

Authors:  Jamie A Browning; Chi Chun Steve Tsang; Xiaobei Dong; Jim Y Wan; Marie A Chisholm-Burns; Christopher K Finch; Jack W Tsao; Colin Liu; Junling Wang
Journal:  BMC Health Serv Res       Date:  2022-02-07       Impact factor: 2.655

5.  Pathophysiological features in the brains of female Spontaneously Diabetic Torii (SDT) fatty rats.

Authors:  Tatsuya Maekawa; Miki Sugimoto; Shinichi Kume; Takeshi Ohta
Journal:  J Vet Med Sci       Date:  2022-01-27       Impact factor: 1.267

6.  Aβ-Induced Alterations in Membrane Lipids Occur before Synaptic Loss Appears.

Authors:  Michiel Van Bulck; Nicola Brandt; Ralf A Claus; Markus Gräler; Anja U Bräuer
Journal:  Int J Mol Sci       Date:  2022-02-19       Impact factor: 5.923

7.  ABCA7 rs3764650 Polymorphism is Associated with Delayed Neurocognitive Recovery.

Authors:  Lu Yu; Haiyan Ji; Minmin Zhou; Yaxin Guo; Junfeng Liu; Daoyun Lei; Chao Han; Tieliang Ma
Journal:  Pharmgenomics Pers Med       Date:  2022-03-30

8.  Binding mode analysis of ABCA7 for the prediction of novel Alzheimer's disease therapeutics.

Authors:  Vigneshwaran Namasivayam; Katja Stefan; Jens Pahnke; Sven Marcel Stefan
Journal:  Comput Struct Biotechnol J       Date:  2021-11-27       Impact factor: 7.271

Review 9.  The Controversial Role of 24-S-Hydroxycholesterol in Alzheimer's Disease.

Authors:  Paola Gamba; Serena Giannelli; Erica Staurenghi; Gabriella Testa; Barbara Sottero; Fiorella Biasi; Giuseppe Poli; Gabriella Leonarduzzi
Journal:  Antioxidants (Basel)       Date:  2021-05-07

10.  Serum Metabolomic and Lipidomic Profiling Reveals Novel Biomarkers of Efficacy for Benfotiamine in Alzheimer's Disease.

Authors:  Ruchika Bhawal; Qin Fu; Elizabeth T Anderson; Gary E Gibson; Sheng Zhang
Journal:  Int J Mol Sci       Date:  2021-12-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.